SavedAdd your journal

Journals / Güncel Retina Dergisi / 2018 / Cilt: 2 - Sayı: 4

Unresponsiveness to Treatment, Pharmaceutical Alterations and Combined Treatments in Behçet’s Disease

Behçet Hastalığında Tedaviye Yanıtsızlık, İlaç Değişimleri ve Kombine Tedaviler

Merih SOYLU
Müge ÇOBAN KARATAŞ
Pages
366–370
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, treatment options for patients with resistant Behcet’s disease that can not be controlled by conventional therapy are discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Behçet’s disease is a multisystem inflammatory disease with chronic recurrences.
📊
Key Findings & Data:Because of the chronic course, the treatment is very difficult.
💡
Conclusion & Impact:In this review, treatment options for patients with resistant Behcet’s disease that can not be controlled by conventional therapy are discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Behçet’s disease is a multisystem inflammatory disease with chronic recurrences. Because of the chronic course, the treatment is very difficult. Classical treatment options are corticosteroids, azothiopurine and cyclosporin. Immunosuppressive agents should be used in addition to steroids in this disease. The aim of the treatment is to protect the visual acuity, reduce the attack frequency, reduce the severity of the attack and to taper off the steroids as early as possible. Although agents used in classical therapy have limited adrenocorticotropic side effects, they each have serious potential side effects, require strict follow-up, and may develop resistance or non-response to these agents. In patients with resistant Behçet’s disease, which can not be controlled by conventional treatment, the first choice should be interferon or biological agents. In this review, treatment options for patients with resistant Behcet’s disease that can not be controlled by conventional therapy are discussed.

Özet

Behçet hastalığı kronik rekürren seyirli multisistemik inflamatuvar bir hastalıktır. Kronik seyrinden ötürü tedavisi oldukça zordur. Klasik tedavi seçenekleri kortikosteroidler, azotiopürin ve siklosporindir. Bu hastalıkta steroidlere ek olarak mutlaka immünsüpressif ajanlar kullanılmalıdır. Tedavide amaç görme keskinliğinin korunması, atak sıklığı, atak şiddetinin azaltılması ve steroidlerin mümkün olduğunca erken kesilmesi olmalıdır. Klasik tedavide kullanılan ajanların adrenokortikotropik yan etkileri sınırlı olsa da, her birinin ciddi potansiyel yan etkileri mevcuttur, sıkı takip gerektirir ve bu ajanlara direnç ya da cevapsızlık gelişebilir. Klasik tedaviyle kontrol altına alınamayan dirençli Behçet hastalarında ilk tercih interferon veya biyolojik ajanlar olmalıdır. Bu derlemede klasik tedaviyle kontrol altına alınamayan dirençli Behçet hastalarındaki tedavi seçenekleri tartışılmıştır

🔖

Cite This Article

SOYLU, M., KARATAŞ, M. Ç. (2018). Unresponsiveness to Treatment, Pharmaceutical Alterations and Combined Treatments in Behçet’s Disease. Güncel Retina Dergisi, Cilt: 2 - Sayı: 4, 366–370. https://ajindex.com/articles/190653

References (10)

  1. Tugal-Tutkun I. Behçet’s Uveitis. Middle East Afr J Ophthalmol. 2009;16(4):219-224. Gül A. Behçet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005:4:81-83.
  2. Jiang Y, Zang M, Li S. Serum PLR and LMR in Behçet’s disease. Can they show the disease activity? Medicine (Baltimore). 2017;96:21. Ozdal PC, Ortaç S, Taskintuna I, Firat E. Long-term therapy with low-dose cyclosporin A in ocular Behçet’s disease. Doc Ophthalmol. 2002;105:301- 312. Nussenblatt RB, Palestine AG. Cyclosporin immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986;31:159-169.
  3. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322:281-285.
  4. Mc Nally TW, Damato EM, Murray PI, Denniston AK, Barry RJ. An update on the use of biologic therapies in the management of uveitis in Behçet’s disease:a comprensive review. Orphanet J Rare Dis. 2017;12(1):130. Yazici H, Ozyazgan Y. Medical management of Behçet’s syndrome. Dev Ophthalmol. 1999;31:118-31.
  5. Hatemi G, E. Seyahi E, Fresko I, Talarico R, Hamuryudan V. One year in review 2016: Behçet’s syndrome.Clin Exp Rheumatol 2016; 34 (Suppl. 102):S10-S22. Kotter I, Gunaydin I, Zierhut M, Stübiger N. The use of interferon alpha in Behçet’s disease:review of the literature. Semin Arthritis Rhheum. 2004;33:320-335.
  6. Hatemi G, Silman, Bang D, Bodaghi B, Chamberlain AM, Gul A et al.: EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656-62.
  7. Kötter I, Hamuryudan V, Öztürk ZÖ, Yazıcı H: Interferon therapy in rheumatic diseases: state of the art 2010. Curr Opin Rheumatol 2010; 22: 278- 83. Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Huong du LT et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007; Mar;91(3):335-9.
  8. Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon- alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 2006;244(12):1692-5,
  9. Gueudry J, Wechsler B, Terrada C, Gendron G, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol 2008; Dec;146(6):837-44.
  10. Sobacı G, Erdem U, Durukan AH, Erdurman C, Bayer A, Köksal S et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet’s uveitis refractory to con